Fatty Cysts on Liver: Causes and Treatment

Fatty cysts on the liver is a term many people encounter after an ultrasound or scan, yet it covers two distinct clinical conditions: simple liver cysts and fatty liver disease (hepatic steatosis). Understanding which condition applies to you, how it is diagnosed on the NHS, and what treatment or lifestyle changes may help is essential for managing your liver health effectively. This article explains the key differences, outlines the symptoms that should prompt a GP visit, and sets out the evidence-based management options available within UK clinical practice.

What are fatty cysts on the liver and are they serious?

Simple liver cysts are usually benign and rarely serious, while fatty liver disease carries a meaningful risk of progression to cirrhosis if underlying causes such as obesity or excess alcohol are not addressed.

The term 'fatty cysts on the liver' is a lay phrase rather than a recognised clinical diagnosis. It is commonly used to describe two distinct but sometimes overlapping conditions: simple liver cysts and fatty liver disease (hepatic steatosis). Understanding the difference between them is important, as their causes, risks and management differ considerably.

Simple liver cysts are fluid-filled sacs that develop within the liver tissue. They are usually benign, do not contain fat, and in most cases cause no symptoms or complications. Fatty liver disease, by contrast, refers to an accumulation of fat within liver cells and is not a cyst in the strict clinical sense, though imaging scans can sometimes make fatty deposits appear cyst-like to patients unfamiliar with radiology reports.

Fatty liver disease is broadly divided into two types. Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is linked to obesity, type 2 diabetes, high cholesterol and insulin resistance.^[1][2] Alcohol-related liver disease (ALD) is caused by excessive alcohol consumption. Both conditions exist on a spectrum:

• Simple steatosis: Fat accumulation with little or no inflammation, generally reversible

• Steatohepatitis: Fat plus inflammation, carrying a higher risk of progression

• Fibrosis and cirrhosis: Advanced scarring that can impair liver function significantly

Simple liver cysts are rarely serious and seldom require treatment. However, some cysts have features that warrant closer attention. Cysts with internal septations, thickened or irregular walls, or mural nodules are described as complex and require further investigation to exclude biliary cystic neoplasms or other pathology.^[17] Polycystic liver disease, a hereditary condition causing multiple cysts, also requires specialist assessment. Hydatid cysts, caused by tapeworm infection, are uncommon in the UK but should be considered in people with relevant travel or exposure history.

Fatty liver disease, particularly when associated with inflammation, carries a meaningful risk of progression to cirrhosis and liver failure if underlying causes are not addressed. Early identification is therefore important, and neither condition should be dismissed without proper clinical assessment. The NHS page on NAFLD/MASLD and the British Liver Trust provide accessible patient-facing information on both conditions.

How are liver cysts and fatty liver disease diagnosed on the NHS?

Diagnosis begins with liver function tests and fibrosis scoring tools in primary care, followed by ultrasound imaging and, where indicated, FibroScan, CT, MRI or liver biopsy under NICE NG49 guidance.

Liver cysts and fatty liver disease are most commonly identified through a combination of blood tests and imaging. Many cases are found incidentally during scans performed for unrelated reasons, such as abdominal pain or gallstone assessment. NICE guidance (NG49) supports a structured, risk-based pathway for investigating suspected MASLD, beginning in primary care; routine population screening for MASLD is not recommended.^[2][3]

Blood tests used in initial assessment typically include:

• Liver function tests (LFTs): Measuring enzymes such as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which may be elevated in fatty liver disease

• Fasting glucose and HbA1c: To assess for type 2 diabetes or insulin resistance

• Lipid profile: Elevated triglycerides and cholesterol are common in MASLD

• Full blood count and clotting studies: To assess overall liver health

Before a diagnosis of MASLD is confirmed, other causes of liver disease are usually excluded. This typically includes testing for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), iron studies (to exclude haemochromatosis), and, where clinically indicated, autoimmune liver markers and coeliac serology.

Fibrosis risk stratification is a key step in the UK pathway. In primary care, non-invasive scoring tools such as the FIB-4 index or the NAFLD Fibrosis Score are used to estimate the likelihood of significant fibrosis.^[2][14] People with an indeterminate or high score are referred for enhanced liver fibrosis (ELF) testing, which provides a more precise assessment.^[2][14] ELF results, together with clinical findings, guide decisions about referral to specialist hepatology services. The British Society of Gastroenterology (BSG) guideline on abnormal liver blood tests provides detailed referral thresholds used in UK practice.

Imaging investigations include:

• Ultrasound: A widely used first-line tool that can identify fatty changes and cysts, though it cannot reliably distinguish between simple and complex cysts

• CT or MRI scanning: Used when ultrasound findings are inconclusive or when a cyst appears complex, irregular or symptomatic

• FibroScan (transient elastography): A non-invasive test that measures liver stiffness as a surrogate for fibrosis, increasingly available in NHS hepatology services

In some cases, a liver biopsy may be recommended to confirm the degree of inflammation or fibrosis, though this is reserved for situations where non-invasive tests are insufficient.

If you have received an abnormal scan result and are unsure of the next steps, your GP is the appropriate first point of contact.

What symptoms should prompt you to see a GP?

Persistent fatigue, upper right abdominal discomfort, unexplained weight loss or nausea warrant a GP appointment; jaundice, abdominal swelling or vomiting blood require immediate emergency assessment.

Most people with simple liver cysts or early fatty liver disease experience no symptoms at all, but certain signs should prompt a timely GP appointment rather than a wait-and-see approach. Because the liver has considerable functional reserve, symptoms often only emerge once the disease has progressed, making awareness of warning signs particularly important.

Symptoms that warrant a GP appointment include:

• Persistent or unexplained fatigue that does not improve with rest

• A dull ache or discomfort in the upper right abdomen

• Unexplained weight loss or loss of appetite

• Nausea that is not explained by another cause

• Abdominal bloating or a sensation of fullness

Symptoms that suggest more advanced liver disease and require prompt medical review include:

• Yellowing of the skin or whites of the eyes (jaundice)

• Dark urine or pale, clay-coloured stools

• Swelling of the abdomen (ascites) or legs (oedema)

• Easy bruising or prolonged bleeding from minor cuts

• Confusion or difficulty concentrating (which may indicate hepatic encephalopathy)

• Vomiting blood or passing black, tarry stools (melaena), which may indicate gastrointestinal bleeding and requires immediate emergency assessment

If you develop jaundice, significant abdominal swelling, vomiting blood or sudden severe abdominal pain, call 999 or attend your nearest accident and emergency department immediately. For other urgent concerns, contact NHS 111 for advice. For less urgent but persistent symptoms, a routine GP appointment is the appropriate route.

A cyst that grows rapidly, becomes painful or is associated with fever may require more urgent investigation to exclude infection or, rarely, malignancy. Your GP can arrange appropriate imaging and refer you to a hepatologist or gastroenterologist if needed.

Treatment options for liver cysts and fatty liver disease in the UK

Simple cysts are monitored and only treated if symptomatic or complex; fatty liver disease management focuses on weight loss, glycaemic control and alcohol reduction, as no pharmacological treatment is currently licensed for MASLD in the UK.

Treatment depends on the underlying cause, the severity of the condition and whether symptoms are present. The management of simple liver cysts differs substantially from that of fatty liver disease, and it is important not to conflate the two.

For simple liver cysts, no treatment is required in the majority of cases beyond periodic monitoring with ultrasound. Intervention is considered when a cyst is large enough to cause symptoms, is growing rapidly or shows features that raise concern on imaging. Cysts managed actively are typically referred to hepatology or hepatobiliary (HPB) surgery services. NHS options may include:

• Aspiration and sclerotherapy: A minimally invasive procedure in which the cyst is drained and a sclerosing agent is injected to prevent refilling

• Surgical fenestration (deroofing): Removal of part of the cyst wall, typically performed laparoscopically, to allow drainage into the abdominal cavity

• Surgical resection: Reserved for very large, recurrent or complex cysts

For fatty liver disease, management is centred on addressing underlying risk factors. As of the time of writing, there is no pharmacological treatment specifically licensed for MASLD in the UK; readers should check current MHRA and NICE guidance for the latest position, as this is an active area of research. NICE NG49 notes that pioglitazone or vitamin E may be considered in adults with biopsy-proven steatohepatitis (NASH) in selected circumstances, under specialist oversight and on an off-label basis; this is not a routine first-line option.^[2][3] Key management strategies include:

• Weight management: Sustained weight loss of around 5 to 10 per cent of body weight has been shown in clinical studies to meaningfully reduce liver fat (NICE NG49; BSG guidance)^[2][11]

• Glycaemic control: In people with type 2 diabetes, optimising blood glucose management is a priority; some glucose-lowering medicines, including GLP-1 receptor agonists, have shown benefit in reducing liver fat in clinical studies, though this does not constitute a licensed MASLD indication and prescribing decisions depend on individual clinical circumstances^[4][5]

• Lipid-lowering therapy: Statins may be used where cardiovascular risk is elevated

• Alcohol reduction or cessation: Essential in alcohol-related liver disease

Referral to a hepatologist is recommended for people with evidence of significant fibrosis or cirrhosis. In advanced cirrhosis, transplant assessment may be required, and ongoing specialist care is essential. NICE guidance (NG49 and NG50) supports a structured, multidisciplinary approach to managing advanced liver disease within NHS specialist services.^[2][18]

Can lifestyle changes help manage fatty liver disease long term?

Lifestyle changes are the most effective long-term strategy; a Mediterranean-style diet, at least 150 minutes of weekly exercise and sustained weight loss of 5 to 10 per cent of body weight can halt or reverse early fatty liver disease.

Lifestyle changes are the most effective long-term strategy for managing fatty liver disease, and evidence consistently shows that sustained modifications to diet, physical activity and alcohol intake can halt or even reverse early-stage disease. For people with MASLD in particular, lifestyle intervention is the cornerstone of management recommended by NICE NG49 and NHS clinical pathways.

Dietary changes with the strongest evidence include:

• Reducing overall calorie intake to achieve gradual, sustained weight loss; clinical evidence cited in NICE NG49 and BSG guidance supports a target of around 5 to 10 per cent of body weight as meaningful for reducing liver fat

• Following a Mediterranean-style diet, rich in vegetables, legumes, wholegrains, fish and olive oil, and low in processed foods, refined sugars and saturated fats^[12]

• Limiting or eliminating alcohol, even in MASLD where alcohol is not the primary cause, as it can accelerate liver damage. The UK Chief Medical Officers' low-risk drinking guidelines advise drinking no more than 14 units of alcohol per week, spread across three or more days, with several drink-free days.^[6] One unit is approximately half a pint of lower-strength beer or a single 25 ml measure of spirits^[7]

• Reducing intake of fructose-containing drinks such as fruit juices and sugar-sweetened beverages

Physical activity plays an independent role beyond weight loss. Both aerobic exercise (such as brisk walking, cycling or swimming) and resistance training have been shown to reduce liver fat. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults, and even modest increases in activity levels can produce measurable improvements in liver health.^[8][9]

Weight management support is available through NHS services, including referral to structured weight management programmes and, where clinically appropriate, pharmacological support. Access to NHS weight-management pharmacotherapy depends on national commissioning and local Integrated Care Board (ICB) pathways, and may involve referral to specialist services. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of clinically appropriate options may be considered following assessment.

Long-term success depends on sustainable change rather than short-term restriction. Regular follow-up with your GP, including repeat blood tests and imaging where indicated, allows progress to be monitored and treatment adjusted as needed. People with more advanced fibrosis should remain under specialist hepatology review regardless of lifestyle improvements.

Scientific References

1. Non-alcoholic fatty liver disease (NAFLD).
2. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
3. MASLD NG49 – full guideline PDF (pioglitazone and vitamin E off-label note).
4. Semaglutide (Wegovy) approved to treat form of liver disease.
5. Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
6. Alcohol consumption: advice on low risk drinking.
7. Alcohol units.
8. UK Chief Medical Officers' physical activity guidelines.
9. Physical activity guidelines for adults aged 19 to 64.
10. Resistance training for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis.
11. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis.
12. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of randomized controlled trials.
13. Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials.
14. Economic evaluation of non-invasive test pathways for high-risk MASLD in the United Kingdom.
15. Meta-analysis: Enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases.
16. Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study.
17. Intraductal papillary neoplasm of the bile duct: The new frontier of biliary pathology.
18. Liver disease: applying All Our Health (references NICE NG50 – Cirrhosis in over 16s: assessment and management).

Frequently Asked Questions